ValiGene and Kimeragen announced today that they will merge to create ValiGen, a EuroAmerican functional genomics company. The newly formed ValiGen will combine the genomics platform under development at Valigene with chimeraplasty, the unique gene correction technology being developed at Kimeragen. The new company will pursue commercial opportunities for its technologies in three areas: ValiGen Read more about ValiGene And Kimeragen In Merger To Create Valigen[…]